BIRC5 and pancreatic adenocarcinoma: Our finding that BIRC5 expression in KIRP, LIHC, LUAD, and PAAD was significantly correlated with infiltration of multiple immune cells indicate that BIRC5 may be a potential immunotherapeutic target in these tumors.